Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.84 |
| ▸ | BTK | Q06187 | 1/20 | 0.65 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.58 |
| ▸ | GSK3A | P49840 | 1/20 | 0.57 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.57 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.57 |
| ▸ | ULK1 | O75385 | 2/20 | 0.54 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25001487 | 0.94 | EGFR (0.76) | EGFRBTKLRRK2GSK3AMAPK15 | |
| SCHEMBL27091391 | 0.94 | EGFR (0.75) | EGFRBTKLRRK2GSK3AMAPK15 | |
| SCHEMBL27091454 | 0.93 | EGFR (0.74) | EGFRBTKLRRK2GSK3AMAPK15 | |
| SCHEMBL25001952 | 0.93 | EGFR (0.73) | EGFRBTKLRRK2GSK3AMAPK15 | |
| SCHEMBL23304015 | 0.92 | EGFR (1.00) | EGFRBTKLRRK2GSK3AMAPK15 | |
| SCHEMBL30748473 | 0.90 | EGFR (0.68) | EGFRBTKULK1ALKTTK | |
| SCHEMBL25001760 | 0.90 | EGFR (0.68) | EGFRBTKULK1ALKTTK | |
| SCHEMBL25001554 | 0.89 | EGFR (0.68) | EGFRBTKLRRK2CDK19ALK | |
| SCHEMBL27091519 | 0.89 | EGFR (0.67) | EGFRBTKALK | |
| SCHEMBL25001951 | 0.88 | EGFR (0.66) | EGFRBTKLRRK2ULK1CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4129996-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | EGFR 1/4885BTK 265/4885LRRK2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.